These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 17361225)
61. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone. Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314 [TBL] [Abstract][Full Text] [Related]
62. IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer. Bruchim I; Sarfstein R; Reiss A; Flescher E; Werner H Cancer Lett; 2014 Oct; 352(2):214-9. PubMed ID: 24997432 [TBL] [Abstract][Full Text] [Related]
63. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. García-Echeverría C; Pearson MA; Marti A; Meyer T; Mestan J; Zimmermann J; Gao J; Brueggen J; Capraro HG; Cozens R; Evans DB; Fabbro D; Furet P; Porta DG; Liebetanz J; Martiny-Baron G; Ruetz S; Hofmann F Cancer Cell; 2004 Mar; 5(3):231-9. PubMed ID: 15050915 [TBL] [Abstract][Full Text] [Related]
64. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139 [TBL] [Abstract][Full Text] [Related]
66. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Bielen A; Perryman L; Box GM; Valenti M; de Haven Brandon A; Martins V; Jury A; Popov S; Gowan S; Jeay S; Raynaud FI; Hofmann F; Hargrave D; Eccles SA; Jones C Mol Cancer Ther; 2011 Aug; 10(8):1407-18. PubMed ID: 21659463 [TBL] [Abstract][Full Text] [Related]
67. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine. Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957 [TBL] [Abstract][Full Text] [Related]
68. Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling. Robinson SA; Rosenzweig SA Biochem Pharmacol; 2006 Jun; 72(1):53-61. PubMed ID: 16684509 [TBL] [Abstract][Full Text] [Related]
69. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Walsby E; Lazenby M; Pepper C; Burnett AK Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792 [TBL] [Abstract][Full Text] [Related]
70. [Killing effect of aurora kinase inhibitor ENMD-2076 on acute myelogenous leukemia cells]. Cao H; Li M; Qian WB Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):479-84. PubMed ID: 23086638 [TBL] [Abstract][Full Text] [Related]
71. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Kaulfuss S; Burfeind P; Gaedcke J; Scharf JG Mol Cancer Ther; 2009 Apr; 8(4):821-33. PubMed ID: 19372555 [TBL] [Abstract][Full Text] [Related]
72. Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells. Liu R; Tang W; Han X; Geng R; Wang C; Zhang Z Oncol Lett; 2018 Nov; 16(5):5983-5991. PubMed ID: 30333869 [TBL] [Abstract][Full Text] [Related]
73. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Wahner Hendrickson AE; Haluska P; Schneider PA; Loegering DA; Peterson KL; Attar R; Smith BD; Erlichman C; Gottardis M; Karp JE; Carboni JM; Kaufmann SH Cancer Res; 2009 Oct; 69(19):7635-43. PubMed ID: 19789352 [TBL] [Abstract][Full Text] [Related]
74. Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. Mancini M; Gariboldi MB; Taiana E; Bonzi MC; Craparotta I; Pagin M; Monti E Br J Cancer; 2014 Jun; 110(12):2865-73. PubMed ID: 24853185 [TBL] [Abstract][Full Text] [Related]
78. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Weisberg E; Nonami A; Chen Z; Nelson E; Chen Y; Liu F; Cho H; Zhang J; Sattler M; Mitsiades C; Wong KK; Liu Q; Gray NS; Griffin JD Clin Cancer Res; 2014 Nov; 20(21):5483-95. PubMed ID: 25186968 [TBL] [Abstract][Full Text] [Related]
79. Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells. Teng CL; Yu CT; Hwang WL; Tsai JR; Liu HC; Hwang GY; Hsu SL Ann Hematol; 2013 Mar; 92(3):301-13. PubMed ID: 23180436 [TBL] [Abstract][Full Text] [Related]
80. Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors. Stauffer F; Cowan-Jacob SW; Scheufler C; Furet P Bioorg Med Chem Lett; 2016 Apr; 26(8):2065-7. PubMed ID: 26951750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]